The Demy-Colton Virtual Salon Series brings cutting-edge insights from key opinion leaders in the life sciences and digital health industry. The webinar-based channels include Therapies/Technologies, Master Class Series - C-Suite, Thought Leader Interviews, Business and Finance, and Humans vs Machines: The Trial Prediction Challenge Series.

Sponsorship Opportunities

We are developing our Summer 2021 Virtual Salon featured topics. We welcome new ideas and concepts from our Salon Sponsors. If you would like to become a sponsor of the Demy-Colton Virtual Salons, please contact Lila Taylor at +1.831.588.8594 or LTaylor@demy-colton.com 

To view past Virtual Salons, please scroll to bottom of the page.

UPCOMING VIRTUAL SALONS:

A-Billion-Dollar-Decision-to-Launch-or-Out-License-in-Europe

A Billion Dollar Decision – to Launch or Out-License in Europe

European commercialization can at first sight, appear a little daunting. 30 EAA countries (European Economic Area) plus UK and Switzerland, a population of 370 million, multiple regulatory systems, different reimbursement environments and labor laws, as well as a melting pot of languages and culture. That is why this salon is a must for any CEO considering European commercialization as a strategic option.

With success the rewards of going it alone can be stellar in terms of increased access to your medicines for patients beyond the US and the potential to enhance your market cap exponentially.

The salon draws on the current experience of senior Biotech leaders, highlighting some of the key decision areas including location for the European HQ, timing, phasing and cadence of roll out and perhaps most importantly, the bear traps to avoid!

Please click here to register.

Biographies:

Sean Morgan-Jones, Barry GreeneStephanie Léouzon, David Meeker, Anant Murthy

VIEW RECENT VIRTUAL SALONS:

Ophthalmic-Drug-Delivery-Eye-on-Innovation

Ophthalmic Drug Delivery: Eye on Innovation
Innovative biotech companies are racing to develop unique drug-delivery systems and agents that overcome the many obstacles that have limited the treatment of serious and increasingly common eye problems. Our panelists will outline the trajectory of this industry’s growth and give an overview of the technologies that are advancing it. Many new ocular drug-transport systems and formulations are being designed as noninvasive, early, and more patient-friendly treatments. Our panelists will also provide insight into bringing these treatments from lab to clinical study and market.

Please click here to view on demand.

Biographies:

Laura RandaKerrie Brady, Jeffrey L. Cleland, PhD, Lloyd DiamondMina Sooch

Fundraising-Strategies-for-European-Biopharma-Companies

Fundraising Strategies for European Biopharma Companies

Fundraising for European biopharma companies, especially those that are advancing programs into the clinic, has always been challenging and limiting because of the nature of European public markets. But times may be changing. It appears that the advent of virtual fundraising may be bringing European innovators closer to sources of ex-EU public and private capital. Is this trend real and will it stick? Where does non-dilutive funding fit? Is listing on NASDAQ the answer? What other tools should a CEO and their management team consider as they advance their assets?

Please click here to register.

Biographies:

Nooman HaqueAntonin de Fougerolles, PhD, Denise Scots-Knight, PhD, Tim Knotnerus
Steffen SchusterMartin Welschof, PhD

Humans-vs-Machines-The-Clinical-Trial-Prediction-Challenge-

SPECIAL UPCOMING CHALLENGE:

Humans vs Machines: The Trial Prediction Challenge Series
First Installment

June 30 11:00 - 12:15 PM ET, WITH LIVE Q&A

A first-of-its kind competition: A team of humans will face off against a machine powered by AI to predict multiple mid-stage clinical trial results. Drug development is risky. How do we prioritize? Recent advances in human and machine predictions show great promise, but who is better: humans or machines? The Humans are represented by Diviner and the machines are represented by Molecular Health. This will be the first of four quarterly events. Each quarter contestants will predict several trial outcomes, with industry experts discussing the results, debating what success looks like, and determining winners. 
Who do you think will win?

Please click here to view on demand.

Biographies:

Moderator:

Panelists:

Psychedelics-Get-Serious

Psychedelics Get Serious

No longer are psychedelics the purview of the counterculture, they are going mainstream. Depression, anxiety, pain, addiction, PTSD and other mental health disorders have been intractable and untreatable – until now. Psychedelics have demonstrated their clinical efficacy in treating disorders that affect thousands of people. While they are going mainstream, there are still a number of hurdles to overcome including IP protection and FDA/EMEA approval pathways.  There is light at the end of this “tunnel.” This is the dawn of a new era of therapeutics.

Please click here to view on demand. 

Biographies:

Walter Greenleaf, Adam Gazzaley, Charlie Hartwell, Ronan LevyEkaterina Malievskaia
Berra Yazar-Klosinski

Investing-at-the-Speed-of-Innovation

Investing at the Speed of Innovation

Biotech innovation is moving faster than ever. Cell therapies, gene therapies, and programs aimed at newly understood targets are moving from laboratories to patients at an unprecedented pace. In turn, investors must make ever larger bets on innovations at an earlier stage and with less validating evidence. In this session, we will talk with leading investors and successful innovators to learn how they decide what technologies are going to make it and which are just too early. The rapidly emerging landscape for adeno-associated virus (AAV) based gene therapy will be discussed as a case study where billion-dollar bets are being made despite remaining technical hurdles and development uncertainty. 

Salon resource:

Triangle Insights Group: Betting on Hide and Seek with AAV

Please click here to view on demand.

Biographies:

Christopher Apolito, Sarah Jims, Mike Dombeck, Geoff Glass, Thomas MathersJoe Zenkus

Strategic-Pricing-for-Optimal-Valuation

Strategic Pricing for Optimal Valuation

This session will help leaders think through key pricing issues that will impact their pivotal trials for commercialization, first product launch and business development activities. We will discuss various issues, including taking a country-level perspective, avoiding optimism bias, investing in payer-relevant endpoints, risk mitigation, and why payer research isn’t always the best answer. If you’re a pre-commercial company leader preparing for your first product launch, investing in a new therapeutic area and seeking commercialization partners, this will be a great session for you.

Please click here to view on demand.

Biographies:

Ted Haack, Judy Campagnari, Jessica MartinezDennis Purcell, Denise Scots-Knight

VC-Trends-in-Healthcare-Investing-The-Power-of-Convergence

VC Trends in Healthcare Investing: The Power of Convergence

Leading VC investors will discuss how advances in AI and machine learning, nanotechnology, optics, quantum physics, and advances in engineering are transforming the life sciences industry. Learn how technology-driven convergence will both disrupt and benefit pharma and biotech. These VC partners will discuss why convergence is a critical component for innovation.

Convergence is the integration of engineering, physical sciences and life sciences. Learn about how funding startups that embrace a convergence environment - interdisciplinary teams and scientists that address major challenges within the life sciences - are accelerating drug development and are the key to solving major challenges such as current manufacturing bottlenecks in cell therapy research. Panelists will also discuss case studies and startups showcasing “convergence in action,” from digital health to biotech.

Please click here to view on demand.

Biographies:

Kimberly Ha, Ann DeWitt, Alex Morgan, Benjamin Quiroga

The-Biotech-SPAC-tacular-Reshaping-the-way-healthcare-thinks-about-funding

The Biotech SPAC-tacular: Reshaping the way healthcare thinks about funding
In the past 12-16 months, special purpose acquisition companies, better known as "SPACs" have been making headlines for their high profile, value, and sometimes very sudden entrance to the public markets. Investor interest in biotech & pharma remains hot, whether via SPACs or other funding models, which begs the question: what's driving all the action, and what does it mean for biotech & pharma companies?

Please click here to view on demand.

Salon resource:
Biotech SPAC-Tacular Validates the Future for Quality SPACs

Biographies:

Ann-Hunter Van Kirk, Ali SatvatBrent Saunders, Kevin Sheridan

Sepsis-A-critical-healthcare-burden-needing-rapid-diagnoses-to-improve-patient-outcomes

Sepsis: A critical healthcare burden needing rapid diagnoses to improve patient outcomes

The mortality rate of sepsis patients increases by as much as 8% each hour proper treatment is not started. Sepsis costs the US healthcare system $62 billion and leads to 270,000 deaths annually. Current diagnoses are inadequate – they take too long and sepsis patients do not have time. Furthermore, they are often wrong. This discussion will focus on the burden of sepsis and how we need to change the paradigm.

Salon resource:

Sepsis Alliance: Sepsis Tech brochure

Please click here to view on demand.

Biographies:

Sara Jane Demy, Rick Bright, Prabhavathi Fernandes, Thomas HeymannCiara Kennedy, PhD
John J. Sperzel III

Targeting-mRNA-The-New-Frontier-of-Tailored-Therapeutics

Targeting mRNA: The New Frontier of Tailored Therapeutics

Targeting mRNA is rapidly emerging as a promising strategy to hit a range of previously ‘undruggable’ biological targets. New classes of small molecules have recently been described that alter mRNA translation and stability, either by modulating mRNA itself (mRNA epigenetics), or by targeting mRNA splicing or translation. These revolutionary new approaches offer ‘tuneable’ specificity ranging from all mRNAs down to individual mRNAs. Development of these new drug classes has the potential to lead to therapeutic interventions that can be tailored for specific diseases and disorders. 

 Come hear from a panel of biotech and pharma experts on: 

  • New developments in mRNA targeting
  • Challenges and opportunities
  • What pharma may look for to partner

Salon resources:

Pullan Consulting  WEHI Drug Discovery Capabilities 2021

Please click here to view on demand.

Biographies:

Linda Pullan, PhDRobert A. Copeland, PhD, Joan Heath, PhD, Carolyn Ng, PhDJennifer C. Petter, PhD, David Segal, PhD

value-story-drug-developers

Gain Your Commercial Edge: Define your value story early

In this Virtual Salon, industry leaders will discuss how they’ve pivoted to create and evolve a “value story” throughout the clinical development and commercial planning processes. Biotech executives have always had an exquisite level of focus on the clinical and regulatory hurdles associated with drug development. Their shift to thinking about the “Value Story” or “Third Hurdle” as it is often described, often comes relatively late in the drug development commercialization process. 
Furthermore, the incoming administration’s focus on therapeutic pricing and access may fundamentally change the way in which patients seek and access healthcare. The discussion will focus on how to navigate the barriers and play to win as the game changes with respect to demonstrable value. 

Salon resources:

Peter Pitts: The Value Equation: A Journey Through the Innovation Ecosystem in the Time of Covid
Triangle Insights Group: PMA Capabilities
Triangle Insights Group: Why the Medicare Specialty Threshold Should Not Drive Pricing Strategy

Please click here to view on demand.

Biographies:

Gautam Aggarwal, Judy Campagnari, Wills Hughes-WilsonLorenz Muller, Peter Pitts

The-New-Alchemy-of-Investing-In-Health

The New Alchemy of Investing In Health

Health is undergoing fundamental change. Health care was all about disease, drugs, hospitals and payers. Today we are already moving from disease to prevention. From institutional to individual focus. Health is becoming increasingly personal and the future will look utterly unlike the past. Every aspect of bioscience, medicine and care is about to be revolutionized by a plethora of new possibilities and choice. In this session, investors at the forefront of health transformation talk about the new alchemy of health investing. If the old approaches are increasingly challenged, where do investors seek huge success now?

Please click here to view on demand.

Biographies:

Mike Edelhart, Alexandra Bause, PhD, David Giampaolo, Harald Stock, PhD

How-U-S-Policy-and-Trends-Will-Shape-Healthcare-in-2021

How U.S. Policy and Trends Will Shape Healthcare in 2021

2021 promises to be an eventful year for the biopharma industry as Covid-19 vaccines should be rolling out and the policy implications of a new U.S. Presidential administration become clear. Bloomberg Intelligence analysts will share their outlook for the year ahead, including a discussion of key pandemic, sector performance, drug development and healthcare policy themes.

Please click here to view on demand.

Biographies:

Beth HalpernMarc EngelsgjerdSam Fazeli, Brian Rye

Unexpected-Long-Term-Cardiovascular-Complications-from-Covid-19-Heart-attacks-heart-failure-stroke

COVID-19: Surprising Cardiac Findings & Concern about the Potential Impact

The causative agent of COVID-19, SARS-CoV-2 virus, appears to lead to a multi-system disease that affects the human host widely beyond the respiratory tract.  Acute cardiovascular complications include myocarditis, myocardial infarction, arrhythmia and cardiac arrest.  Case-mortality rate is up to 5-fold higher for those with pre-existing cardiovascular diseases. 

In early reports, detectable cardiac changes are seen in up to 70+% of patients post clinical recovery, including those who have recovered from mild COVID, and young and athletic people with no co-morbidities.  This has potentially enormous implications for long-term cardiovascular health globally given the 50 million world-wide reported cases to date.  We face significant challenges in the diagnosis, monitoring, and treatment of the potential long-term cardiac complications of COVID-19.

Please click here to view on demand.

Biographies:

Sara Jane Demy, Bob S. HuProf. Eike Nagel, Eric Topol

Metabesity

Metabesity: A Healthcare Burden on the Rise

Metabesity, a constellation of the major chronic diseases with metabolic roots affecting an aging population, is on the rise globally. Its societal burden, a mix of chronic, non-communicable diseases, is staggering and growing.

Please click here to view on demand.

Biographies:

Emi Gonzalez, John L. Brooks IIITomas Landh, Christopher Lento, Komathi Stem

Bioelectric-Medicine-Sparking-Innovation-in-Healthcare

Bioelectric Medicine: Sparking Innovation in Healthcare

Electricity as a therapeutic has been used to re-right heartbeats, to stimulate nerves, neurochemicals and cellular regeneration. Today there is a surge of new medical devices being developed and new bioelectrical treatments for everything from treating a host of CNS diseases to cancer and diabetes. This panel of experts will discuss recent research, the favorable regulatory environment and new business models around the electrifying new wave of potential for bioelectrical therapeutics.

Please click here to view on demand.

Biographies:

Beth RogozinskiPaolo Cassano, Juan-Pablo MasRenee Ryan

Fireside-Chat-with-Amy-Abernethy-MD-Principal-Deputy-Commissioner-US-Food-amp-Drug-Administration

The Fusion of technologies: the lines are blurring between physical, digital and biological sciences

Interviewer:

  • Art Pappas, Managing Partner, Pappas Capital

Please click here to view on demand.

Biographies:

Art PappasAmy Abernethy

Women-s-Health-Moves-Mainstream-Rapid-Growth-Meets-Underserved-Market

Women’s Health Moves Mainstream – Rapid Growth Meets Underserved Market

The rapidly growing “Femtech” market is expected to grow to $50B by 2025. Hear from this group of leading private company CEOs, who are heading up innovative advances in technology, that could change the way women's health is treated. The panelists will share perspectives on high-potential investment areas within the space. Learn how these CEOs secured their initial capital and scaled, and hear them discuss how to build better research, policy, data, and care delivery capabilities to achieve venture-level exits and personalized healthcare for half of the global population.

Please click here to view on demand.

Salon resources:

Frost and Sullivan Femtech Executive Summary Links of Interest from Mylene Yao 
Mycovia Corporate Overview Shape the Next Wave of Femtech Innovation

Biographies:

Christina JenkinsPatrick JordanKatherine RyderSurbhi SarnaMylene Yao

Fireside-Chat-with-Mike-Gaito-Global-Head-of-Healthcare-Investment-Banking-JP-Morgan

Fireside Chat with Mike Gaito, Global Head of Healthcare Investment Banking, JP Morgan

Moderator: 

  • Dennis Purcell, Founder, Aisling Capital

Please click here to view on demand.

Biographies:

Dennis PurcellMichael Gaito

Futurescaping-of-Oncology

Futurescaping Of Oncology

Futurescaping of Oncology will explore forward-looking, key, therapeutically relevant technology advances that could change the way we treat cancer. Three novel platforms will be discussed including endogenous reprogramming, targeting RNA, and targeting undruggable protein targets. These new technological innovations were chosen to reflect a range of approaches, risks, degrees of validation, and complexity of engineering. These platforms are excellent examples of higher-level technologies that will take cancer therapies to the next level.

Please click here to view on demand.

Biographies:

Jeffrey Bockman, Jake Becraft, Jennifer C Petter, Arthur T Sands

Lessons-from-Bergamo-Discoveries-in-Treating-Critically-ill-COVID-19-Patients

Lessons from Bergamo: Discoveries in Treating Critically-ill COVID-19 Patients

By now it's clear that many people with COVID-19 severe enough to put them in a hospital face a long recovery. The virus ravages the lungs and other organs in multiple ways. Direct invasion of cells can damage or destroy them and drive massive inflammation throughout the body. Autopsies commonly show arterial thrombosis and severe endothelial damage. Endothelial damage, which can play an early and central pathogenic role in acute respiratory distress syndrome (ARDS) and thrombosis, activates the lectin pathway of complement.

Join Sara Jane Demy, CEO & Founder of Demy-Colton, as she moderates a hematology KOL panel to discuss lessons learned from the front-line in treating critically ill patients in Bergamo, Italy.

This panel will discuss novel pathways in the fight against COVID-19, in particular, the central role of endothelial injury, activation of the complement system and the lectin pathway and thrombosis development in COVID-19.

Please click here to view on demand.

Salon resources:
Slide Decks:
Dr. Laurence slide deckDr. Perales slide deck Dr. Rambaldi slide deck
Other resources:
Treatment with the Lectin-Pathway Inhibitor Narsoplimab TR COVID-19 paper 
Clinical & Experimental Immunology MASP2
 

Biographies:

Sara Jane DemyJeffrey C LaurenceMiguel-Angel PeralesAlessandro Rambaldi

In-Vivo-Gene-Therapy-Personalizing-the-Ultra-Rare-and-Scaling-Up-for-Chronic-Disease

In Vivo Gene Therapy: Personalizing the Ultra-Rare and Scaling-Up for Chronic Disease

Advanced therapeutics, including gene and call therapies, have emerged as significant FDA/EMA approved therapies for several ultra-rare genetic disorders and advanced malignancies.  In the next couple years, many more will be seeking registration using validated in-vivo and ex-vivo gene transfer and modification platforms (AAV, lentiviral, oligonucleotides, gene editing nucleases, etc.) earning a significant role in the healthcare pharmacopeia.  However, while hurdles such as regulation, manufacturing costs, logistics, and reimbursement have limited patient access, pioneers in the gene therapy sector have been reshaping what healthcare delivery looks like for the next wave of innovators. This BioFuture Salon will discuss the state of the art and potential for gene therapies to become more “drug-like” and scalable for either the personalized ultra-rare or more common chronic disorders.

Please click here to view on demand.

Biographies:

Michael C. RiceFaraz AliGeoff McDonoughSapan Shah

Alzheimer-039-s-Like-a-Tsunami-by-the-time-you-see-it-it-is-too-late

Alzheimer's: Like a Tsunami, by the time you see it, it is too late

Alzheimer’s disease is a relentless, fatal disease creating a health crisis for patients, families and nations. If we can’t stop it, the cost to society will be great. Global thought leaders have aligned around a goal to have a treatment that will slow the progression of the disease by 2025. While there have been no positive late-stage studies of investigational medicines in the last decade, the scientific advancement and understanding of AD progression and diagnosis has shifted our knowledge of the disease significantly and led to increased drug development targeting populations in the earliest stages of disease. This evolving scientific understanding of Alzheimer’s disease and the promise that treating earlier than we do today will translate to better patient outcomes.

Please click here to view on demand.

Biographies:

Sara Jane Demy, Phyllis Barkman-Ferrell, Dr. Mylea Charvat, Dr. Howard Fillit, Prof. Craig Ritchie

Drugging-the-Undruggable-The-Power-of-Artificial-Intelligence

Drugging the Undruggable:The Power of Artificial Intelligence

It is estimated that up to 85% of the human proteome is currently "undruggable." These proteins lack easy-to-find pockets where therapeutics can bind. A wave of biotech companies with new technologies have arrived to tackle the problem of overcoming these most elusive drug targets.

Please click here to view on demand.

Biographies:

Sara Jane Demy, Robert J. Schneider, Abraham Heifets, Marian Nakada, Noam Solomon, Alice Zhang

The-Future-of-Healthcare-Innovation-Change-amp-Urgency

The Future of Healthcare: Innovation, Change & Urgency

Two industry titans will explore the metamorphosis that is unfolding in health care, driven by innovation and demanded by consumers, that will profoundly transform this space as we know it.

Please click here to view on demand.

Biographies:

Sara Jane Demy, Jeremy Abbate, Ralph Snyderman